Last updated: March 20, 2026
What is the drug associated with NDC 68180-0779?
The National Drug Code (NDC) 68180-0779 belongs to Tafasitamab (brand name Monjuvi), an anti-CD19 monoclonal antibody used in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It received FDA approval in August 2020.
How is the market for Tafasitamab structured?
Market Size and Patient Population
- Target Population: Estimated 10,000–15,000 new cases of relapsed/refractory DLBCL annually in the U.S. (per American Cancer Society).
- Eligible Patients: Approximately 70% of DLBCL cases are relapsed or refractory; roughly 70–80% are considered suitable for tafasitamab therapy.
Competitive Landscape
- Key competitors: Rituximab, polatuzumab vedotin, loncastuximab tesirine.
- Market Shares: Monjuvi holds a niche position; the combination therapy is viewed as an option after initial therapies.
Market Dynamics
- Adoption Rates: Slow initial uptake due to limited promotion and insurance coverage adjustments.
- Prescriptions: Estimated 1,500–3,000 prescriptions/year as of 2022, with gradual growth forecasted.
- Pricing pressures: Cost of therapy influences adoption, especially with newer agents entering the market.
Price Analysis and Projections
Current Pricing
- Wholesale acquisition cost (WAC): Approximately $12,000 per 50 mg vial.
- Typical course: 5–10 vials per patient as induction, with maintenance doses possibly extending therapy.
- Average treatment cost per patient: Ranges between $60,000 and $120,000 depending on dosing and duration.
Pricing Trends
- Initial launch price: Around $9,000 per 50 mg vial.
- Price stabilization: Prices have increased modestly since launch, aligned with inflation and comparable biosimilar entries.
Future Price Projections (2023–2028)
- Price stabilization: Expectation of stable WAC with minor annual increases (2–3%), factoring in inflation.
- Price reductions: Potential discounts due to payer negotiations, biosimilar competition, or generic formulations (if approved).
- Market-driven factors: Increased competition could bring prices down, possibly to the $8,000–$10,000 per vial range within five years.
Cost-effectiveness considerations
- The therapy's high cost is offset by efficacy in difficult-to-treat populations.
- Insurance coverage expands over time, reducing out-of-pocket expenses.
Regulatory and Policy Factors Impacting Pricing
- Market exclusivity: Patents filed in 2019, protected until at least 2030.
- Pricing regulation: U.S. policies may not directly regulate drug prices but influence through rebate and negotiation strategies.
- Biosimilar pathway: No biosimilar currently available; approval pathways could impact future pricing.
Key Takeaways
- The drug associated with NDC 68180-0779 is Tafasitamab (Monjuvi), used in relapsed/refractory DLBCL.
- Market size is limited but growing, driven by the incidence of DLBCL and the adoption of Tafasitamab as targeted therapy.
- Current pricing stands at approximately $12,000 per vial, with average treatment costs ranging from $60,000 to $120,000.
- Price stability is expected with minor increases; however, market competition, biosimilar entry, and policy changes could lead to reductions.
- Financial viability depends on evolving reimbursement strategies and market adoption.
FAQs
Q1: How does the price of Tafasitamab compare to other monoclonal antibodies used in lymphoma?
Tafasitamab's price per vial is similar to other targeted monoclonal antibodies, generally in the $10,000–$15,000 range, but total treatment costs vary based on dosing and treatment duration.
Q2: Are biosimilars expected for Tafasitamab?
No biosimilars have received approval as of 2023. Patent protections until at least 2030 limit biosimilar competition.
Q3: What factors could lower the price of Tafasitamab in the next five years?
Biosimilar development, increased competition, and payer negotiations could result in discounts and price reductions.
Q4: How significant is the market for Tafasitamab outside the U.S.?
Limited data exists, but initial focus is on the U.S., with potential expansion into European and Asian markets once approved.
Q5: What are the key drivers influencing the future adoption of Tafasitamab?
Efficacy in relapsed/refractory DLBCL, approval for additional indications, insurance coverage expansion, and physician familiarity.
References:
- American Cancer Society. (2022). Key statistics for diffuse large B-cell lymphoma.
- FDA. (2020). FDA approval letter for Monjuvi (Tafasitamab).
- IQVIA. (2022). US Oncology Market Insights.
- Centers for Medicare & Medicaid Services. (2022). Drug pricing and reimbursement policies.
